Stock Traders Purchase Large Volume of Call Options on Medline (NASDAQ:MDLN)

Medline (NASDAQ:MDLN – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 10,954 call options on the stock. This is an increase of approximately 289% compared to the average volume of 2,819 call options.

Medline Stock Up 2.9%

MDLN traded up $1.09 during midday trading on Wednesday, hitting $38.77. The company had a trading volume of 24,834,164 shares, compared to its average volume of 7,872,284. The stock’s 50 day moving average price is $35.39 and its 200 day moving average price is $39.31. Medline has a 52 week low of $31.37 and a 52 week high of $50.88. The company has a quick ratio of 2.51, a current ratio of 4.04 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $50.99 billion and a price-to-earnings ratio of 87.78.

Medline (NASDAQ:MDLN – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12. Medline had a return on equity of 8.21% and a net margin of 1.84%. The firm had revenue of $7.86 billion during the quarter. On average, research analysts anticipate that Medline will post 1.58 earnings per share for the current fiscal year.

Insider Transactions at Medline

In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the sale, the insider directly owned 20,231,483 shares in the company, valued at $715,182,924.05. This represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 6,348,676 shares of company stock valued at $224,525,137 over the last ninety days. 0.81% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC raised its position in Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after purchasing an additional 254 shares in the last quarter. Allworth Financial LP boosted its position in shares of Medline by 36.8% during the third quarter. Allworth Financial LP now owns 1,439 shares of the company’s stock valued at $50,000 after purchasing an additional 387 shares in the last quarter. Covestor Ltd grew its holdings in Medline by 31.8% in the third quarter. Covestor Ltd now owns 1,953 shares of the company’s stock worth $68,000 after purchasing an additional 471 shares during the period. NewEdge Advisors LLC grew its stake in shares of Medline by 100.0% in the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 475 shares during the last quarter. Finally, Reyes Financial Architecture Inc. bought a new position in Medline in the 3rd quarter valued at approximately $30,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Stifel Nicolaus cut their target price on Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Wells Fargo & Company lowered their price objective on Medline from $45.00 to $34.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 11th. Deutsche Bank set a $37.00 price objective on Medline and gave the stock a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, November 9th. Finally, Tigress Financial cut their target price on shares of Medline from $62.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Twenty-three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.08.

View Our Latest Research Report on Medline

About Medline

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Further Reading

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.